

THE ORGANISATION FOR PROFESSIONALS IN REGULATORY AFFAIRS

VETERINARY ANNUAL SYMPOSIUM

Regulators and Industry – some common approaches to improving the regulatory environment

Thursday 8th October 2009

Clarion Hotel, – Ringvägen, Stockholm, Sweden

Organised in conjunction with

Swedish Medical Products Agency

Conference working party

Ray Harding – Cyton Biosciences Ltd - chair

Henrik Holst - MPA, Sweden

Rick Clayton – IFAH-Europe

Mária Szabó - Central Agriculture Office, Directorate of Veterinary Medicinal Products, Hungary

Melanie Leivers – EMEA

Guillaume Agède - Ceva Santé Animale

Veterinary Symposium	
	Thursday 8 th October 2009
8:30	Registration, Coffee and Exhibition
0.00	
9:00	Opening Remarks: Henrik Holst - Associate Professor, Head of Veterinary Section, MPA, Sweden
	Session I: Keynote presentations on the opportunities for re-organisation of the regulation of veterinary medicines in Europe
of the v Europe an effic	t session will bring together the three main strings shaping the direction of the forthcoming review eterinary medicines legislation; the HMA Reflection Paper on opportunities for improvement, the an Commission's impact assessment on the legislative options, and the HMA Strategy to develop ient European medicines regulatory network. erson: Rick Clayton – IFAH-Europe
9:10	"Opportunities for improving legislation" HMA Reflection Paper: Progress since 2008
	Catherine Lambert - International Affairs, AFFSA, France
09:40	Review of Veterinary Legislation in 2010, Impact Analysis in 2009
09.40	Martin Terberger- Directorate-General for Enterprise and Industry – Head of Pharmaceuticals Unit, European Commission, Belgium
10:10	Progress on HMA Strategy for an efficient European Medicines Regulatory Network HMA Management group representative - TBC
10:40	Coffee and Tea
10:40	Coffee and Tea
10:40	Coffee and Tea Session II: Outcomes of recent joint focus group meetings and joint workshops
This s impler	
This s impler discus	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd
This s impler discus	Session II: Outcomes of recent joint focus group meetings and joint workshops Session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline
This s impler discus Chairpe	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd
This s impler discus Chairpe 11:10	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden
This s impler discus Chairpe	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the assion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009)
This s impler discus Chairpe 11:10	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden
This s impler discus Chairpe 11:10 11:30	Session II: Outcomes of recent joint focus group meetings and joint workshops Session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden
This s impler discus Chairpe 11:10	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009)
This s impler discus Chairpe 11:10 11:30	Session II: Outcomes of recent joint focus group meetings and joint workshops Session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden
This s impler discus Chairpe 11:10 11:30 11:50	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark
This s impler discus Chairpe 11:10 11:30	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark Antimicrobial Resistance – follow-up from the joint HMA/EMEA workshop (20 May 2009)
This s impler discus Chairpe 11:10 11:30 11:50	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark
This s impler discus Chairpe 11:10 11:30 11:50 12:10	Session II: Outcomes of recent joint focus group meetings and joint workshops Session will address how regulatory authorities foresee the nentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark Antimicrobial Resistance – follow-up from the joint HMA/EMEA workshop (20 May 2009) Valerie Thomas, Intervet/Schering-Plough; Chair of IFAH-Europe Anti-infectives working party
This s impler discus Chairpe 11:10 11:30 11:50 12:10 12:30	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the assion that took place with industry on key issues prson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark Antimicrobial Resistance – follow-up from the joint HMA/EMEA workshop (20 May 2009) Valerie Thomas, Intervet/Schering-Plough; Chair of IFAH-Europe Anti-infectives working party Panel Discussion
This s impler discus Chairpe 11:10 11:30 11:50 12:10	Session II: Outcomes of recent joint focus group meetings and joint workshops Session will address how regulatory authorities foresee the nentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark Antimicrobial Resistance – follow-up from the joint HMA/EMEA workshop (20 May 2009) Valerie Thomas, Intervet/Schering-Plough; Chair of IFAH-Europe Anti-infectives working party
This s impler discus Chairpe 11:10 11:30 11:50 11:50 12:10 12:45	Session II: Outcomes of recent joint focus group meetings and joint workshops session will address how regulatory authorities foresee the nentation of recent scientific and administrative guidelines and the ssion that took place with industry on key issues erson: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark Antimicrobial Resistance – follow-up from the joint HMA/EMEA workshop (20 May 2009) Valerie Thomas, Intervet/Schering-Plough; Chair of IFAH-Europe Anti-infectives working party Panel Discussion Lunch
This s impler discus Chairpe 11:10 11:30 11:50 11:50 12:10 12:30 12:45 This se initiative	Session II: Outcomes of recent joint focus group meetings and joint workshops Session will address how regulatory authorities foresee the mentation of recent scientific and administrative guidelines and the ession that took place with industry on key issues prison: Ray Harding – Cyton Biosciences Ltd CVMP Oncology Guideline Fredrik Hultén - MPA, Sweden CVMP Bioequivalence Guideline (6 May 2009) Karolina Törneke - MPA, Sweden Electronic Submissions workshop (7 May 2009) Per Helboe - Senior Director of Licensing Division, Danish Medicines Agency, Denmark Antimicrobial Resistance – follow-up from the joint HMA/EMEA workshop (20 May 2009) Valerie Thomas, Intervet/Schering-Plough; Chair of IFAH-Europe Anti-infectives working party Panel Discussion Lunch Session III: CMDv initiatives - bringing efficiencies to the system ssion will provide an update on the CMDv 2009 work plan and will be illustrated by the policy

	Esther Werner - Chair CMDv, Paul-Ehrlich-Institut, Germany
14:05	Labelling Initiatives view of CMDy one year on
14.05	
	Labelling Initiative; view of CMDv one year on Christophe Debruyne - Federal Agency for Medicines and Health Products, Belgium
14:25	Labelling Initiative; view of industry one year on
	Veena Singh - Manager Veterinary Medicine Regulatory Affairs & Market Support, Pfizer Animal Health, UK
14:45	Panel Discussion
15.00	Coffee and tea
	Session IV: Better regulation - bringing efficiencies to the system
	sion will cover the on-going and new initiatives and proposals for better regulation in the
	ry sector.
Chairper	
	Variations: making the system work
	Melanie Leivers - Deputy Head of Sector, Veterinary Marketing Authorisation Procedures, EMEA
15:50	Pharmacovigilance update
10.00	Ton Kamphuis - College ter Beoordeling van Geneesmiddelen, NL
	 NTA Vol. 9B, work-sharing PSURs Work-sharing PSUR's
16:10	IFAH-Europe proposals for review of PV Chapter in 2010
	Sylvie Meillerais - IFAH-Europe
16:30	Panel discussion
	Closing remarks – Henrik Holst, MPA Sweden and Ray Harding, Chair of TOPRA Conference Working Party and Veterinary Special Interest Network